Time for a new episode of Tomorrow! Today we're talking about business insolvencies. In 2024, they shot up by 10% and we expect back-to-back increases in 2025 and 2026. Tune in to find out what factors are at play, with Allianz Research's AI Assistant Aria.
Read the full report here: Riders on the storm: Managing uncertainty - updated outlook - https://www ... Show More
Jul 21
Allianz Pulse 2025: Confused and disappointed – but less pessimistic
Time for a new episode of Tomorrow! Today we’re unpacking the results the Allianz Pulse. For the seventh edition, we surveyed 6,000 people across six of Europe’s largest economies: Germany, France, Italy, Spain, Poland, and Austria, taking the pulse on future prospects, policymak ... Show More
4m 31s
Jul 7
Mid-year economic outlook 2025-26: Summertime sadness
The global economy has got that summertime, summertime sadness. Global GDP growth could hit the slowest pace since 2008 this year, outside of recession periods, according to our mid-year economic outlook for 2025-26. The US is expected to grow by +1.6%, helped by lower effective ... Show More
4m 39s
Jun 18
The transatlantic divide in Working Capital Requirements
Time for a new episode of Tomorrow! Today, we’re diving into a crucial – but often overlooked – indicator of business health: Working Capital Requirements. WCR is the financial canary in the coal mine, revealing how efficiently companies are managing cash flows, inventories, and ... Show More
4m 38s
Jun 2023
101: Biotechnology and Healthcare: A New Dawn? With Bob Bradway, CEO of Amgen
The late Steve Jobs of Apple said “I think the biggest innovation of the 21st century will be at the intersection of biology and technology, a new era is beginning”.
If you want see how biotech can change the world of health, whilst potentially being capable of creating extraordi ... Show More
39m 55s
Jul 30
ICYMI: AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US.Revenue climbed 12% to $14.5 billion, the UK drugmaker said Tuesday, beating estimates. Earnings per share excluding some i ... Show More
14m 39s
Apr 2024
Can WeightWatchers survive the Wegovy era?
WeightWatchers is struggling. Launched in the early 1960s, the brand grew by helping members shed pounds through behavioural change programmes. Then, GLP-1 anti-obesity drugs hit the market, long-time spokesperson and board member Oprah Winfrey announced her departure, and the co ... Show More
17m 23s
Jul 2024
#358 🤓 Autoimmunity & Cancer Connections with Dr. Paul Anderson, NMD
Send us a textThis week on The Less Stressed Life Podcast, I am excited and honored to be joined by Dr. Paul Anderson, a recognized educator and clinician in integrative and naturopathic medicine with a focus on complex chronic illness and cancer. In this episode, we get super ne ... Show More
1h 16m
Apr 2025
#346 - Scaling biotech and improving global health: lessons from an extraordinary career in medicine | Susan Desmond-Hellmann, M.D., M.P.H.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter Susan Desmond-Hellmann is a physician and scientist whose remarkable career has spanned clinical medicine, oncology, biotech innovation, and global ... Show More
2h 5m